Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 18.8901 USD -3.52% Market Closed
Market Cap: 116.5m USD
Have any thoughts about
Aligos Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one ALGS stock under the Base Case scenario is 10.9774 USD. Compared to the current market price of 18.8901 USD, Aligos Therapeutics Inc is Overvalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALGS Relative Value
Base Case
10.9774 USD
Overvaluation 42%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
74
Median 3Y
73.5
Median 5Y
73.5
Industry
8.1
Forward
35
vs History
vs Industry
Median 3Y
-10.5
Median 5Y
-11.5
Industry
23
Forward
-5.4
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-12.9
Industry
23.4
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-12.7
Industry
27.3
vs History
92
vs Industry
67
Median 3Y
9.9
Median 5Y
13.9
Industry
2.6
vs History
vs Industry
85
Median 3Y
64.5
Median 5Y
64.5
Industry
8.1
Forward
7.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
11
vs Industry
16
Median 3Y
-9.5
Median 5Y
-9.7
Industry
4.3
Forward
-0.3
vs History
7
vs Industry
15
Median 3Y
-9.3
Median 5Y
-10.9
Industry
3.8
Forward
-0.2
vs History
5
vs Industry
19
Median 3Y
-10.6
Median 5Y
-11.3
Industry
6
vs History
5
vs Industry
15
Median 3Y
-10.5
Median 5Y
-11.2
Industry
3.8
vs History
vs Industry
74
Median 3Y
56.5
Median 5Y
59.3
Industry
4.8

Multiples Across Competitors

ALGS Competitors Multiples
Aligos Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Aligos Therapeutics Inc
NASDAQ:ALGS
118.7m USD 14.9 -1.6 -0.3 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59.1 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 4.9 37.5 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD 11.9 -264.2 26.8 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 4.1 912.5 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 6.4 19 17.4 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
US
Aligos Therapeutics Inc
NASDAQ:ALGS
Average P/E: 212.4
Negative Multiple: -1.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.1
412%
US
Amgen Inc
NASDAQ:AMGN
37.5
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -264.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
912.5
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Aligos Therapeutics Inc
NASDAQ:ALGS
Average EV/EBITDA: 17.9
Negative Multiple: -0.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Aligos Therapeutics Inc
NASDAQ:ALGS
Average EV/EBIT: 23.2
Negative Multiple: -0.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top